Introduction
The synthetic oestrogen fosfestrol tetrasodium (Honvan) has been proposed to be of bene®t in both localised and advanced prostate cancer. Its precise mode of action remains a matter for debate although it seems to possess direct tumoricidal activity as well as yielding oestrogen analogues as its metabolites. 1 Clinical studies published thus far have reported variable disease response to intravenous infusions of Honvan, whether given in low or high dose infusions. One such study 2 incorporating its own data into a literature review reported no objective responses, although a subjective improvement in symptoms in 75% of patients. Anecdotal evidence suggests that certain well-selected patients, including those with ureteric obstruction, may bene®t from Honvan. 3 Our series examined symptom relief, with or without objective disease response, in a group of patients with advanced disease treated with intravenous Honvan for acute symptomatic presentations. Our indications for treatment thus were either prompt stabilisation of symptoms before starting maintenance therapy, or as secondary therapy in apparently hormone-refractory disease.
Methods
Case notes of patients having received Honvan in the setting of advanced prostate cancer (CaP) were reviewed retrospectively. Parameters identi®ed were: age at diagnosis of CaP; age at which Honvan was prescribed for symptoms; symptom (or disease process, such as acute obstructive uropathy); disease pattern (such as lymphadenopathy or bony metastases); degree of differentiation as determined by prostate biopsy (Gleason grade where available) and concurrent treatment at time of presentation with symptoms. Each patient was grouped according to whether they received Honvan de novo or as secondary therapy.
Response to infusion of Honvan was measured simply in terms of subjective response (symptomatic improvement as judged by the patient), objective response (such as radiological regression of lymphadenopathy), and reduction in serum concentration of PSA. Survival after onset of Honvan infusion was noted, as were any potential confounding factors in symptom relief. Patients without evidence of extraprostatic disease were not considered in this series.
Infusions comprised 1104 mg Honvan daily for 5 d prior to September 1996, 1200 mg daily for 7 d subsequent to this, representing standard hospital formulary regimes at these times in our unit. Each infusion was given over a standard 30 min, diluted to a volume of 250 ml with 0.9% saline, and preceded by an infusion of metoclopramide as an antiemetic. All infusions were given on an inpatient basis.
Results
A total of 21 patients who received Honvan infusions were eligible for inclusion in this series. Notes for three of these patients were unavailable for review. One patient failed to continue with the infusion beyond its commencement because of intolerable vomiting. Review of 17 patients' notes are presented in Tables 1 and 2 , giving individual patterns of disease. In total, there were 21 courses of treatment for the 17 patients, as mentioned above. Twelve of the 21 represented de novo treatment of disease, three of these receiving Honvan concurrently with another hormonal agent; nine of the 21 were given as secondary therapy. Three patients received more than one course of Honvan over the course of their disease (one received three courses and two received two courses).
In patients receiving Honvan alone de novo (9), seven had symptoms from bulk abdominopelvic disease (one had lymphoedema of legs, two had bilateral lower limb DVT, two had lower tract obstruction, two had ureteric obstruction). One patient presented with purpura and thrombocytopaenia, and one with symptoms of cord compression. All nine had objective evidence of improvement, although eight reported subjective symptomatic improvement (the patient who did not presented an acute renal failure secondary to ureteric obstruction). Eight patients had a documented fall in PSA. Three patients received Honvan de novo along with a concurrent hormonal therapy (one with lower tract obstruction and two with bone pain). The patient with lower tract symptoms had both subjective and objective improvement, and one of the patients with bone pain similarly.
All nine patients receiving Honvan as secondary therapy had bony metastases. Three of these nine episodes were associated with subjective improvement (one patient with bone pain, and one patient with two separate episodes of ureteric obstruction, who had concurrent drainage on both occasions with stabilisation of renal function when mechanical drainage was withdrawn). In six out of nine episodes there were no documented response.
Nine patients had died having had Honvan during the period of review. Three patients had repeated infusions. The mean survival time after ®rst infusion was about 20 months (range 2 weeks to 93 months). There were no cardiovascular complications nor episodes of intractable emesis during or after infusions in the 17 patients.
Discussion
Honvan infusions were well tolerated by all except one patient in our study, reiterating the acceptability of this mode of therapy and possibly indicating its use on an outpatient basis. Nausea and vomiting have been reported as common side-effects of oestrogen administration, although more worrying potential effects are those of thromboembolic phenomena hypertension and oedema. 4 From the point of view of thrombotic events, our series reiterates the experience of a number of studies, 5 and there is evidence that the intravenous route may even be safer than the oral route. 6 Pharmacokinetic studies 7 have demonstrated that peak plasma levels of fosfestrol are achieved very quickly, with rapid clearance of the principal metabolites. Pharmacokinetic pro®les seem not to be affected by daily repeated administration, nor by renal impairment, an important determinant given the ages of our patients and obvious tendencies towards renal impairment. Its use in advanced disease, particularly in those patients in whom the disease had become hormone-resistant has been proposed to arise from its direct action on tumour cells, rather than purely in in¯uencing hormonal activity. Animal studies have demonstrated that fosfestrol decreases the ratio of epithelial to stromal density, 1 and that it inhibits protein synthesis directly in human tissue culture. 8 Overall, our series compares well with published series that reported similar dose regimes to those used here. Cetrin et al 9 reported 25 patients, in whom 3 out of 18 showed greater than 50% drop in plasma PSA levels, ®ve showed subjective improvement and two with cardiovascular events. Ferro et al 10 reported 29 patients in whom 13 showed greater than 50% drop in plasma PSA, 22 showed subjective improvement and three with cardiovascular events were noted.
In our series, patients with stigmata of bulk pelvic or intrabdominal disease, causing ureteric obstruction, urethral obstruction or venous or lymphatic obstruction, did best. In two patients with spinal cord compression, one patient gained good symptomatic and objective clinical bene®t from Honvan alone (de novo). The other patient continued to deteriorate generally, with no improvement in his incontinence or leg weakness despite surgical decompression (secondary therapy). The response seen in patients with bone pain from bony metastases, or those presenting in pre-renal failure adds weight to the argument that Honvan bene®ts a group of patients who have bulk disease causing an obstructive phenomenon, rather than those who clearly have an overwhelming metastatic burden, or who are approaching the end of a deteriorating disease state.
Conclusions
The issue of intravenous Honvan as de novo hormonal treatment is interesting. Eight out of 12 patients receiving Honvan in this setting had acute symptoms of bulk disease; the others had symptoms attributable to bony metastases. Rapid stabilisation of an acute presentation may be a key indication for its use before investigating maintenance therapy: the pharmacokinetic data referenced above would support this although there are no data comparing Honvan with other modes of therapy. This would seem eminently amenable to a prospective trial.
In`excaping' disease, some response to Honvan is obtained occasionally (about a third in our group). Our patient who received Honvan twice (along with surgical drainage) for acute ureteric obstruction and maintained renal function when drainage was discontinued, tenuously supports the assertion that it may be appropriate in those patients with bulk locoregional disease causing obstructive phenomena, rather than those with diffuse metastatic cancer. The argument for a prospective trial of Honvan for secondary therapy in such patients is less compelling; it must be considered however that since Honvan is safe, with relatively few complications compared to acute disease-related events in advanced prostate cancer, trial-based evidence for or against a bene®cial effect would allow an earlier decision to be made for invoking palliative care in end-stage patients. We believe, therefore that a prospective randomised trial of Honvan infusion in this setting would bene®t these patients' management.
Intravenous Honvan is a safe, acceptable mode of therapy which may be effective in selected patients. Whilst we await the results of trials in its use for localised disease, there is a need to re®ne the indications for its use in symptomatic advanced disease, which will consolidate a powerful weapon in the armamentarium of the urological oncologist. 
